Ibogaine Treatment for Heroin
DATE: 21.04.2021
Age: 55
GENDER: MALE WEIGHT BEFORE: 143.5KGS
WEIGHT AFTER: 133.5KGS ALTURA/HIGH: 1.83MTS
Heroin Treatment Duration
The patient underwent a 9-day ibogaine treatment regimen with no booster doses administered during this period. This comprehensive blood report illustrates a patient’s health parameters before and after ibogaine treatment. Each parameter will be discussed separately, highlighting any noteworthy improvements observed post-treatment.
1- Blood Pressure
Before ibogaine treatment, the patient exhibited elevated blood pressure, ranging from 140/92 mmHg to 167/111 mmHg. Following treatment, there wa a
4- Oxygen Saturation (SATO2)
SATO2 levels, a measure of blood oxygenation, remained stable throughout the treatment period. Although they slightly fluctuated between 90% and 96%, no significant alterations from the normal range were noted, indicating no adverse effects on respiratory function due to ibogaine treatment.
5- Cell Blood Counting
Post-treatment, lymphocyte counts decreased while neutrophil counts increased, contributing to better immune system balance. Eosinophil counts also slightly increased. Hb, hematocrit, red blood cell, and platelet counts displayed improvements, with values generally increasing post-treatment.
7- Biochemistry
Biochemical parameters showcased enhancements post-treatment, including glucose levels, ureic nitrogen, urea in serum, creatinine, uric acid, and HEROINE levels. Notably, glucose levels normalized, ureic nitrogen and urea in serum decreased, and creatinine and uric acid levels improved. The presence of HEROINE in the pre-treatment report indicates a potential substance use issue that should be addressed separately.
8- Lipid Profile
The lipid profile, which includes total cholesterol, LDL cholesterol, HDL cholesterol, and VLDL cholesterol, is not provided in the dataset, limiting the assessment of changes in lipid parameters.
9- Liver Function Test
Data on liver function tests, such as AST, ALT, total bilirubin, indirect bilirubin, direct bilirubin, LDH, and GGT, suggest relatively normal liver function with no significant changes before or after treatment.
10- Other Parameters
The dataset includes information on A1C hemoglobin, C-reactive protein, urinalysis, total testosterone, antibodies against Epstein-Barr, cytomegalovirus, and thyroid function tests. These parameters did not exhibit substantial changes related to ibogaine treatment.
11- Urine Test for Drugs
Before treatment, the patient tested positive for opioids (OPI), benzodiazepines (BZD), and THC but negative for amphetamines (AMP) and methamphetamine (MET). Post-treatment, the patient remained positive for BZD and was now negative for opioids (OPI) but still positive for THC. This indicates ongoing substance use, particularly benzodiazepines and THC.
Conclusion
In conclusion, the provided blood report suggests improved blood pressure, heart rate, glucose levels, and certain blood cell parameters following ibogaine treatment. However, it is crucial to address the continued positive tests for benzodiazepines and THC, indicating ongoing substance use issues. Additionally, lipid profile data would be essential for a comprehensive evaluation of cardiovascular health. As always, further clinical evaluation and intervention by healthcare professionals are recommended to effectively assess the patient’s overall health and treatment outcomes.